Hybio Pharmaceutical Co.. Ltd.
Industry Group: Pharmaceuticals
Country/Region: China
Identifier: SHE:300199
Hybio Pharmaceutical Co Ltd is engaged in manufacturing and sale of peptide products. The company's peptide finished dosage products include digestive system agents, immune modulators, hormone and endocrine modulators, antiviral agents, and hemostatic products. It also provides peptide CRO and CMO services, as well as API products.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 885 out of 921
Universe
Global Universe 14952 out of 16216
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Pacira Biosciences, Inc. |
27.7
Medium
|
408 out of 921 |
Kiniksa Pharmaceuticals Ltd. |
29
Medium
|
480 out of 921 |
Luye Pharma Group Ltd. |
31
High
|
583 out of 921 |
Hybio Pharmaceutical Co.. Ltd. |
39.7
High
|
885 out of 921 |
Guobang Pharma Ltd. |
40.6
Severe
|
898 out of 921 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Hybio Pharmaceutical Co.. Ltd.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Hybio Pharmaceutical Co.. Ltd.'s Management of ESG Material Risk is Weak